Article Sidebar

pdf
Date Published: 07/09/2024
Abstract Views: 47
Views pdf: 41
DOI: https://doi.org/10.51298/vmj.v541i3.10902
Issue
Vol. 541 No. 3 (2024)
Section
Các bài báo
How to Cite
Hoàng, V. T., Đặng, M. P., & Nguyễn, T. H. (2024). THE RELATIONSHIP BETWEEN THE POLYMORPHISM RS1801320 IN THE RAD51 GENE AND THE STATUS OF ER, PR, AND HER-2 RECEPTORS IN BREAST CANCER PATIENTS. Vietnam Medical Journal, 541(3). https://doi.org/10.51298/vmj.v541i3.10902

THE RELATIONSHIP BETWEEN THE POLYMORPHISM RS1801320 IN THE RAD51 GENE AND THE STATUS OF ER, PR, AND HER-2 RECEPTORS IN BREAST CANCER PATIENTS

Văn Tuân Hoàng, Minh Phương Đặng, Thị Hương Nguyễn

Main Article Content

Abstract

Objective: This study aims to determine the relationship between the polymorphism rs1801320 in the Rad51 gene and the status of ER, PR, and HER-2 receptors in breast cancer patients. Subjects and Methods: A cross-sectional study was conducted on 300 breast cancer patients at K Hospital – Tan Trieu. Results: The genotype distribution of the rs1801320 polymorphism in breast cancer patients was as follows: GG (72.3%), GC (23.7%), and CC (4.0%). The allele frequency of G (84.2%) was higher than that of C (15.8%). The positive expression rates for ER, PR, and HER-2 receptors were 66.3%, 52.7%, and 52.3%, respectively. Our study did not find a statistically significant association between the genotype and allele frequency of the rs1801320 polymorphism of the Rad51 gene and the status of ER, PR, and HER-2 receptors in breast cancer patients. Conclusion: The rs1801320 polymorphism of the Rad51 gene is not associated with the status of ER, PR, and HER-2 receptors in breast cancer patients.

Article Details

Keywords

breast cancer, Rad51, rs1801320

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
2. Reference SNP (rs) Report rs1801320 - dbSNP - NCBI. Accessed May 24, 2019. https://www.ncbi.nlm.nih.gov/snp/rs1801320
3. Gupta P, Sambyal V, Guleria K, et al. Association of RAD51, XRCC1, XRCC2, and XRCC3 Polymorphisms with Risk of Breast Cancer. Genet Test Mol Biomark. 2023;27(7):205-214. doi: 10.1089/gtmb.2023.0012
4. Tuân HV, Thúy NT, Hà VVV, Thịnh TH, Tiến NV. Mối liên quan giữa đa hình đơn nucleotide của gen rad51 và nguy cơ mắc ung thư vú. Published online 2020.
5. Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study. Arch Iran Med. 2016;19(10):680-686. doi:0161910/AIM.003
6. Cao SS, Lu CT. Recent perspectives of breast cancer prognosis and predictive factors. Oncol Lett. 2016; 12(5):3674-3678. doi:10.3892/ ol.2016.5149
7. Baqer M, Al-Harmooshee H, Shaheed O, Al-Taei. Germline Mutation of RAD51 Single Nucleotide Polymorphisms as Susceptibility Factor for Breast and Ovarian Cancer. Syst Rev Pharm. 2020;11:100-108. doi:10.31838/srp.2020.10.17
8. Lan NguyenH, Laohasiriwong W, Stewart JohnF. Survival probability and prognostic factors for breast cancer patients in Vietnam. Glob Health Action. 2013;6(1): 18860. doi:10.3402/gha. v6i0.18860
9. Tulbah S, Alabdulkarim H, Alanazi M, et al. Polymorphisms in RAD51 and their relation with breast cancer in Saudi females. OncoTargets Ther. 2016;9:269-277. doi:10.2147/OTT.S93343
10. Al Hamad M, Kussaibi H, Alkharsah KR, et al. Polymorphic Variants in 5′-UTR Regions of the RAD51 Gene are Associated With RAD51 Expression and Triple-Negative Breast Cancer (TNBC): A Case-Control Study. Appl Immunohistochem Mol Morphol. 2021;29(4):270. doi:10.1097/PAI.0000000000000900